MK-677 (Ibutamoren)
Also known as: Ibutamoren, Nutrobal, MK677, L-163,191
MK-677 is a research compound not approved for human use. For informational and research purposes only.
Overview
Oral non-peptide growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release without injection. Long half-life (~24 hours) enables once-daily oral dosing. Widely researched for body composition, sleep quality, and IGF-1 elevation.
Research Summary
MK-677 binds the ghrelin receptor (GHS-R1a) to stimulate pulsatile GH release and increase circulating IGF-1. Unlike peptide GHRPs it survives oral administration. Clinical trials demonstrate significant increases in GH pulsatility and IGF-1 without suppression of the endogenous GH axis, though long-term use raises glucose metabolism concerns.
Dosing Range
low
10mg
moderate
25mg
high
50mg
Units: mg · Frequency: once daily oral
Dosing ranges are aggregated from preclinical research and community protocols. Not medical dosing guidance.
Administration Routes
Reconstitution Notes
Oral compound — no reconstitution needed. Typically supplied as capsules or liquid solution. Store at room temperature away from light.Step-by-step reconstitution guide →
Supplies you'll need
Affiliate links — Research Stack may earn a small commission at no extra cost to you.
Reported Side Effects
- Water retention
- Increased appetite
- Elevated fasting glucose (long-term)
- Fatigue (initial, transient)
- Carpal tunnel syndrome (high doses)
- Elevated prolactin
- Lethargy / morning grogginess
Research Papers
2 peer-reviewed sourcesCommunity Experiences
Aggregated from public forums. Anecdotal — not clinical evidence.
Community reports on oral dosing protocols, sleep improvements, and managing water retention with MK-677.
View original threadOverview
MK-677 (ibutamoren) is a non-peptide, orally active growth hormone secretagogue developed by Merck in the 1990s. Unlike GHRP peptides that require injection, MK-677 survives digestion due to its small-molecule structure and achieves systemic bioavailability after oral administration.
Its primary distinction is a ~24-hour half-life, enabling once-daily dosing — a major practical advantage over injectable GHRPs that must be dosed multiple times per day. This makes MK-677 one of the most convenient GH-stimulating compounds in the research toolkit.
Mechanism
MK-677 is a potent, selective agonist of the ghrelin receptor (GHS-R1a). By mimicking acylated ghrelin, it:
- Stimulates pulsatile GH release from the anterior pituitary
- Increases IGF-1 production in the liver (the primary anabolic mediator)
- Does not suppress endogenous GH axis — the natural feedback loop remains intact
- Increases appetite via NPY/AgRP hypothalamic neurons (the same pathway as ghrelin)
Unlike exogenous GH administration, MK-677 works through the natural pulsatile release mechanism, preserving the physiologic pattern of GH secretion.
GH Axis Effects
| Parameter | Effect | |-----------|--------| | GH pulse amplitude | ↑↑↑ | | IGF-1 | ↑↑↑ | | Cortisol | ↔ (minimal) | | Prolactin | ↑ (mild) | | Fasting insulin | ↑ (long-term concern) | | Appetite | ↑↑ |
Dosing Notes
- 10mg/day: Lower IGF-1 increase; fewer side effects; often used for sleep and recovery
- 25mg/day: Research-standard dose; significant IGF-1 elevation; moderate water retention
- 50mg/day: Maximum studied; greater water retention and glucose effects; used in short-cycle contexts
Timing: Best taken at night with food to blunt the appetite surge and allow GH pulse during sleep.
Glucose and Metabolic Considerations
A key finding in long-term MK-677 research is mild insulin resistance. GH itself is counter-regulatory to insulin, so sustained GH elevation can impair fasting glucose over weeks. This is the primary reason MK-677 cycles are limited in length and why metabolic monitoring is relevant in research protocols.
Related Performance Peptides
ACE-031
PerformanceACVR2B-Fc · ActRIIB-Fc fusion protein
Soluble form of activin type IIB receptor (ActRIIB-Fc fusion protein) that acts as a myostatin and activin trap. Blocks…
CJC-1295
PerformanceCJC-1295 DAC · CJC-1295 without DAC (Mod GRF 1-29)
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog. It stimulates the pituitary gland to release gro…
CJC-1295 / Ipamorelin Stack
PerformanceCJC-1295 Ipamorelin · Mod GRF 1-29 Ipamorelin
The CJC-1295 (without DAC) and Ipamorelin combination is the most widely researched and community-validated growth hormo…